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A B S T R A C T
The use of oncolytic viruses forms an appealing approach for cancer treatment. On the one hand the viruses
replicate in, and kill, tumor cells, leading to their intra-tumoral amplification. On the other hand the viral
infection will activate virus-directed immune responses, and may trigger immune responses directed against
tumor cells and tumor antigens. To date, a wide variety of oncolytic viruses is being developed for use in cancer
treatment. While the development of oncolytic viruses has often been initiated by researchers in academia and
other public institutions, a large majority of the final product development and the testing of these products in
clinical trials is industry led. As a consequence relatively few pre-clinical and clinical studies evaluated different
oncolytic viruses in competitive side-by-side preclinical or clinical studies. In this review we will summarize the
steps and considerations essential in the development and characterization of oncolytic viruses, and describe our
multidisciplinary academic consortium, which involves a dozen departments in three different Dutch uni-
versities, collaborating in the development of oncolytic viruses. This consortium has the ambition to develop a
small series of oncolytic viruses and to evaluate these in various cancers.
1. Brief introduction on viro-immunotherapy
Oncolytic viruses are viruses that either have a natural preference to
enter, replicate in, and/or kill cancer cells as opposed to normal cells, or
are engineered to do so. Therefore, they are widely studied as anti-
cancer agents in what is called oncolytic virotherapy. In the early
1900s, the first observations were recorded of potential anti-cancer
effects by viruses, e.g. a leukemia patient that went briefly into spon-
taneous remission after contracting a presumed influenza infection [1].
In the 1950s, when techniques for virus growth, purification and
characterization became available, this remarkable phenomenon was
further investigated [2]. A variety of clinical trials were initiated, but
due to somewhat disappointing results and safety concerns, oncolytic
virotherapy lost interest as chemotherapy gained ground. The general
idea at that time was that oncolytic viruses punched a hole in the tumor
and were then cleared by anti-viral immunity. It was in the early 1990s
when oncolytic viruses gained renewed interest, due to a change in the
dogma: oncolytic viruses were no longer regarded as simple cancer cell
killers, but instead as potent inducers of strong, long-lasting anti-cancer
immunity. Thus, oncolytic virus therapy is now considered a novel form
of immunotherapy, i.e. viro-immunotherapy. The rising numbers of
publications on oncolytic virus therapy demonstrate the increased in-
terest in the topic ever since [3]. The notion that oncolytic viruses are
reputable anti-cancer agents is continuously growing, highlighted by
the approval T-VEC in 2015 in the United States (U.S.), the European
Union (E.U.) and Australia for treatment of a subset of patients suffering
from advanced melanoma.
1.1. Some advanced oncolytic viruses
T-VEC is an oncolytic herpes simplex virus lacking its ribonucleotide
reductase gene and expressing granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) [4]. In light of this approval, herpes simplex
virus is intensively studied and accounts for nearly a quarter of all
ongoing clinical trials using oncolytic viruses. This enveloped virus
harboring a dsDNA genome is currently tested for the treatment of
various cancer types (including gastrointestinal cancer, breast cancer,
melanoma, and brain cancers), both as a single agent and in combi-
nation with other anti-cancer therapies.
In addition to herpes simplex viruses, adenoviruses are ‘popular’
oncolytic viruses accounting for another quarter of all ongoing clinical
trials investigating oncolytic virotherapy. Adenovirus is a non-
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enveloped virus with a dsDNA genome. The rise of recombinant DNA
techniques in the 1980s, relative straightforward genetic modification,
high-titer virus batches, and a good safety profile in clinical trials have
made adenovirus one of the most frequently studied viruses in vaccine
development, gene therapy, and oncolytic virotherapy. Because of this
widespread application in several research areas, extensive knowledge
is at hand about virus biology, virus-host interactions, immune mod-
ulation, and therapeutic application.
Roughly another quarter of clinical trials for oncolytic virotherapy is
performed with vaccinia virus. This is an enveloped dsDNA poxvirus of
which extensive data is available about safety in humans due to its
prolonged use as a vaccine virus for the smallpox eradication programs.
Together with a high transgene packaging capacity, vaccinia virus is an
attractive platform for oncolytic virotherapy design.
Other regularly used oncolytic viruses include reovirus, measles
virus, Newcastle disease virus, vesicular stomatitis virus, Maraba virus,
Coxsackievirus, poliovirus, and retrovirus. Reovirus is a non-enveloped
dsRNA virus that possesses natural oncolytic properties and is not as-
sociated with serious human disease. Clinical trials have demonstrated
the safety of reovirus administration, and it is currently tested for ef-
ficacy in a variety of studies for several cancer types [5,6].
Measles virus is an enveloped negative-sense RNA virus that is the
causative agent for measles disease. Oncolytic measles virus is based on
vaccine strains of the virus, and preferentially lyses tumor cells through
recruitment of CD46 as its receptor [7,8]. Its proven safety record,
stability, and the feasibility to incorporate transgenes, make it a very
attractive candidate for anti-cancer therapy. However anti-cancer effi-
cacy may be hampered by anti-viral host immunity [8].
Another enveloped negative-sense RNA virus, Newcastle disease
virus (NDV), is a virus with a natural avian host range that also displays
tumor killing and the level of virulence in birds correlates with the
degree of oncolysis [9]. Research efforts primarily focus on the gen-
eration of NDVs with improved efficacy and safety profiles. Several
modified strains of NDV have been generated harboring therapeutic
transgenes, and have demonstrated anti-cancer potency in a variety of
clinical trials [10].
Vesicular stomatitis virus (VSV) is a negative-sense RNA rhabdo-
virus virus, has natural tumor specificity, a fast replication cycle, and
potent immunomodulatory properties. Importantly, elevated doses
seem to cause toxicities and, to date, only a pseudotyped VSV vaccine
vector, lacking the G gene and instead containing the non-neurotropic
glycoprotein of lymphocytic choriomeningitis virus (LCMV), and an
attenuated oncolytic VSV expressing human interferon β have pro-
ceeded to clinical trials [11].
Maraba virus is also a rhabdovirus and shows some homology with
VSV. No virus-related pathology has been reported in humans, and the
prevalence of anti-viral antibodies is negligible, making it an interesting
agent for virotherapeutic purposes. Safety and immunogenicity have
been demonstrated in early-phase clinical trials and follow-up studies
are currently performed in monotherapy as well as combination
therapy approaches [12].
Coxsackievirus is a picornavirus harboring a positive-sense RNA
genome and a prevalent human pathogen. This non-enveloped virus
also has oncolytic potency, and Coxsackievirus A21 is currently eval-
uated in several clinical trials. Administration appears to be safe
without serious adverse events. As the viruses can give severe disease in
humans, care should be taken in evaluating this virus in clinical trials,
and attenuation may be necessary [13].
Another positive-sense RNA virus, poliovirus, is a neurotropic virus
that has been genetically modified to attenuate neurovirulence and
retain cancer-specific cytotoxicity [14]. The resulting PVSRIPO virus
has shown successful targeting of glioblastoma and has been granted
“breakthrough therapy” and fast track designations by the U.S. Food
and Drug Administration (FDA), expediting research into poliovirus
therapy [15].
Toca 511 is a replication-competent retroviral vector based on a
modified murine leukemia virus that specifically infects actively di-
viding cells. Its tumor selectivity is presumably enhanced by defects in
anti-viral immunity. The combination of Toca 511 and the prodrug
Toca FC has obtained the “breakthrough therapy” and fast track des-
ignations by FDA, as well as Priority Medicine designation from the
European Medicines Agency (EMA), and is currently tested in a large
phase III trial in patients with recurrent high grade glioma [16].
1.2. Human vs non-human viruses
Humans are the natural host of many of the studied oncolytic
viruses. The efficacy of oncolytic virus therapy could be severely im-
peded by pre-existing immunity in the human population. Although
conflicting data is reported on this, neutralizing antibodies may reduce
the infectivity, penetration, and spread of the viruses. To circumvent
this, viruses that are rare or absent in the human population have been
studied as alternative oncolytic agents. Some of these have proceeded
to clinical trials in humans, such as rare serotype adenoviruses and
Newcastle disease virus [17,18]. While this approach may by-pass the
barrier of pre-existing immunity, it could bring along new biological
risks with regard to potential virus adaptation to the human hosts [19].
These genetic alterations should be closely examined to rule out pos-
sible changes to key features of the virus, e.g. affecting shedding, sta-
bility, and human-to-human transmission.
2. Development of viro-immunotherapy as a concerted action of
disciplines
The therapeutic platform of oncolytic viruses encompasses many
different aspects, and therefore the clinical development of this therapy
is dependent on a multidisciplinary approach. Virology expertise is
needed for the production of viruses and the characterization of the
virus cycle in tumor cells in vitro and in vivo. The success of future
clinical studies can be greatly affected by the identification and the
control of the factors that are important for viral entry, replication,
spread, oncolysis, and immune activation. These factors can differ be-
tween the various oncolytic viruses, between tumor types, and in fact,
between individual cancer patients. Better stratification of patients,
therefore, is warranted. Moreover, information on the immune com-
position of the various cancer types is essential, as well as insight in the
immunological consequences of the viro-immunotherapy. On top of
that, in-depth knowledge on the (molecular) biology of the different
cancer types and their bidirectional heterotypic interactions with the
supportive microenvironment is needed. What is known about the
mutations that drive progression of the cancer cells, the proportion and
properties of cellular and extracellular surrounding stroma? What are
prognostic markers of tumor progression? How do the tumors escape
from destruction by conventional therapeutic approaches? And lastly, a
firm basis of medical data should be available on the effects and impact
of conventional therapies, which could set the baseline for the standard
of care, and which could form a basis of historical control data to be
used as comparator in the initial experiments with viro-im-
munotherapy.
3. Viro-immunotherapy application
In the past decade(s), immunotherapy has become a hot topic in the
field of cancer therapy. Many approaches are being explored, including
cancer vaccines, CAR-T cells, checkpoint inhibitors, and viro-im-
munotherapy. The approval of T-VEC by the FDA and EMA may pave
the way for other oncolytic viruses to reach the clinic. Most clinical
trials using oncolytic viruses as a monotherapy have shown at least a
single round of virus replication and transgene expression (if encoded
by the virus), followed by moderate anti-cancer activity. Importantly,
multiple oncolytic viruses show durable albeit moderate clinical ac-
tivity, which is increased when combined with other chemotherapeutic
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and immunotherapeutic agents [20]. Nevertheless, many viro-im-
munotherapies are outcompeted by alternative (non-viral) approaches
that show similar effects. Therefore, a major focus of the viro-im-
munotherapy research field focuses on obtaining potency-enhanced
viruses. Oncolytic viruses offer a promising therapeutic option in par-
ticular for the treatment of cancers that are nearly always fatal, diffi-
cult-to-treat, and with limited improvement by other treatment strate-
gies. The development of effective treatments for such aggressive
cancer types including pancreatic cancer, advanced prostate cancer and
glioblastoma is lagging. Patients suffering from these tumors have a
very poor prognosis, with 5-year overall survival rates between 3–31 %
[21–25], warranting the urgent need for novel innovative treatment
options.
4. Determinants of tumor sensitivity and therapeutic efficacy
Importantly, tumors are very heterogeneous and complex entities,
that are often partially susceptible and partially resistant to oncolytic
viro-immunotherapy [4]. This has led to partial therapeutic responses
and relapses. There are many barriers to overcome before oncolytic
viruses can reach and eradicate a tumor. First, a physical barrier of
endothelial cells, abnormal lymphatic and vascular networks, tumor-
associated fibroblasts, and dense layers of extracellular matrix can
impair the efficient infiltration of the viruses and immune cells into the
tumor. Moreover, tumors generally exist in an immunosuppressive
tumor microenvironment (TME), escaping immune surveillance, di-
viding rapidly, and disseminating to distant locations. They secrete
many factors that suppress the activity of immune cells and may recruit
immunosuppressive cells. Therefore, upon reaching the tumor, onco-
lytic viruses need to retain their infectivity within an im-
munosuppressive environment. On the other hand, they can induce
strong innate anti-viral immune responses upon intracellular viral
sensing, or by interactions with antigen-presenting cells (APCs). Fur-
thermore, the viruses can be bound by pre-existing antibodies or
complement factors in the circulation, hampering effective tumor in-
fection, although therapy-enhancing effects of pre-existing immunity
have also been reported [26–28]. Therefore, it may be challenging to
get sufficient amounts of the viruses at the tumor site before they are
cleared by the host’s immune system. Once the viruses reach the tumor,
a productive virus infection must be established. Viruses commonly
infect cells by interacting with cell surface receptors. Cancers can
downregulate the expression of these receptors, thus impeding viral
entry. After virus entry, intracellular anti-viral mechanisms should be
evaded and the cellular genome replication as well as protein produc-
tion machineries should be hijacked to allow for efficient virus multi-
plication. Lastly, the virus should exit the cells to allow for viral spread.
Ideally, the virus escapes through the induction of immunogenic cell
death rather than a ‘clean’ form of cell death, since the ‘sterile’ release
of dead cell components as well as virus particles presumably leads to
very little immune stimulation. Overall, immunological effects seem to
be more crucial than oncolytic effects. Effects on immune (memory)
cells generally are long-lasting, as opposed to direct oncolytic effects
that will stop when the viruses are cleared. Moreover, immunological
effects can be systemic, despite the absence of virus at distant locations.
5. Patient stratification
In most clinical studies only a single oncolytic virus was evaluated.
This virus was often chosen on the basis of availability for the study.
Also remarkably, few pre-clinical studies compared the anti-tumor ef-
ficacy of different oncolytic viruses. In order to rank oncolytic viruses
for use in a particular patient group, the anti-tumor efficacy of different
oncolytic viruses should be compared in a single model. The results of
such comparative studies can be used to identify determinants of sus-
ceptibility to virus infection, oncolysis, and immune activation, and
may allow the generation of predictive molecular tumor signatures that
aid in selecting the best available virus for a patient cohort. In a next
step such approaches may also allow to select an oncolytic virus that
may be more likely than others to be efficacious in a particular patient,
in other words matching a virus to an individual patient. The genera-
tion of predictor profiles can thus be exploited to stratify patients and
design personalized therapeutic plans. Treatment personalization re-
quires reliable prediction of an individual patient’s response. Therefore,
relevant models that represent the inter-patient heterogeneity are cru-
cial.
5.1. Preclinical and ‘near-patient’ models
Many in vitro studies are performed in monolayer cultures of cancer
cell lines, which likely do not optimally represent the patient’s cancer
and the complex multicellular interactions found in vivo. To maximize
the therapeutic relevance of findings in the laboratory, models that
faithfully represent the patient’s tumor (i.e. ‘near-patient’ models) are
needed. A key uncertainty in extrapolating the experimental results
obtained in such models is to what extent these models represent the
tumor in the patient, and how we can assure that the outcomes of ex-
periments with these models have a predictive value for the clinical
situation.
We and others have shown that serum-free cultures of glioblastoma
patient-derived tumor cells are a useful model for anti-cancer drug
screenings [29,30]. They are superior to serum-supplemented cultures
with regard to the tumors’ genetic makeup, gene expression profile,
histological phenotype in xenografts, and recapitulation of the intra-
and inter-tumoral heterogeneity [31]. Using this model system, we
have established a large biobank of patient-derived gliomas that have
been molecularly characterized. The predictive value of such a drug-
screening platform has been highlighted by a significant correlation
between the response of clinical and corresponding patient-derived cell
culture upon temozolomide (TMZ) treatment, the standard of care
agent for the glioma patients [32]. Importantly, the results of screen-
ings can be correlated with known molecular features of the tumors,
possibly revealing predictive markers of response to treatment as well
as insight into underlying pathways. Currently, the potencies of several
oncolytic viruses are evaluated on the glioma cells, and correlated to
molecular tumor properties such as gene expression and secreted fac-
tors (unpublished data).
Actual tumors are three-dimensional structures, as opposed to two-
dimensional cell cultures. To incorporate the three-dimensional char-
acter of tumors in a model system, spheroid culture models can be used.
It seems easier for a virus to reach all tumor cells in a monolayer than in
the three-dimensional structure of actual tumors. Interestingly, we have
previously found that some tumor cells resist oncolytic reovirus infec-
tion in monolayer, whereas the cells are efficiently infected as spheroids
[33]. Receptor expression seems not to be the only determinant of
susceptibility to virus infection. We demonstrated that spheroids secrete
high amounts of cathepsins (like many tumors). These enzymes can
extracellularly convert the virus particles into a form that can infect
cells independent of the canonical receptor. This process mimics the
proteolytic activation of the reovirus particles in the endosomes.
Spheroids can be grown from patient tumor cells as well. These
spheroids may represent the tumor cells more genuinely and therefore
the clinical relevance of cells in spheroid culture may be higher than the
same cells grown in monolayer cultures. Moreover, tumor stroma cells
can be incorporated in the spheroids, to better represent the composi-
tion of patient tumors [34–36]. Alternatively, spheroids can be derived
directly from fresh tumor tissue by cutting the tissue into small pieces,
which round up in culture. Such structures, known as organotypic
multicellular spheroids, retain the characteristics of the primary tumor
including the presence of stroma, immune cells, and endothelial cells
and have proven to be a versatile model for studying viral infection,
penetration and oncolysis in three-dimensional setting (Fig. 1, upper
panel) [37].
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Similarly, thin slices of fresh patient-derived tumor material can be
generated and maintained in vitro. This culture system was originally
established for breast tumors [38], but has subsequently been extended
to other cancer types including pancreatic adenocarcinoma [39],
glioma [40], prostate [41,42], and bladder cancer [42]. This model
incorporates the stromal cells and natural architecture of the tumor,
allowing the monitoring of infection, penetration, and spread in a three-
dimensional clinically relevant tumor model (Fig. 1, lower panel).
Another approach is to grow the tumors on the chorioallantoic
membrane (CAM) of embryonated chicken eggs. In this model, tumors
are implanted on the CAM, which is easily accessible by making a
window in the egg shell. This system incorporates a functioning blood
circulation, albeit consisting of non-human cells. It has proven useful to
study pro- or anti-angiogenic agents, metastasis formation, and intra-
tumoral spread of oncolytic viruses [43].
Animal models (e.g. syngeneic tumors in mice, other rodents, or
spontaneous tumors in dogs) not only contain the tumor but also a
blood circulation and a functional immune system. Typically, tumor
cell lines are implanted into the rodents to grow tumors; these however
are not representative for the tumor diversity and heterogeneity en-
countered in patients. Although the syngeneic model is useful to test
general toxicity and immune responses to treatment, it may therefore
have limited predictability for the patients, considering the large inter-
and intra-tumoral variation. Another limitation is that various oncolytic
viruses have a narrow host range, e.g. adenovirus does not replicate
efficiently in murine cells, whereas most preclinical studies are per-
formed in mice. Alternatively, patient-derived xenograft (PDX) models
can be used, in which human material is engrafted in immunodeficient
mice [44]. When using patient-derived tumor tissues, this system may
retain the molecular characteristics of the original tumor, the tissue
architecture, the stromal components, and the inter- and intra-tumoral
heterogeneity. Therefore, it may reflect with some accuracy the com-
plex interactions between tumor cells and tumor microenvironment in
the patient. However, xenograft model experiments require substantial
amounts of patient resection material, as well as time and money.
Notably, xenograft models usually cannot be used to study the effect of
immune modulation as this requires immune-competent models. Con-
sequently, the downsides of available mouse models pose a challenge in
selecting a suitable in vivo model for preclinical OV testing. It may
therefore be useful to test virotherapy approaches in alternative ‘near-
patient’ model systems to predict the potential antitumor efficacy of
particular oncolytic viruses.
5.2. Data and sample collection from OV trials
Apart from the development of representative in vitro and in vivo
models to study heterogeneity in response to various OV strains, efforts
should be made to gain as much information as possible from clinical
trials testing these agents. Comprehensive clinical data as well as
clinical samples such as blood, post-treatment tissue biopsies or CSF can
allow correlation of patient response to clinical parameters, molecular
features or specific biomarker profiles of the patient or tumor and
should therefore be collected and stored as much as possible, if not for
prospective analysis then for future retrospective validation studies.
Such an approach was taken for an oncolytic measles virus tested in
glioblastoma patients. Analysis of sensitive versus resistant PDX xeno-
grafts identified constitutive interferon pathway activation as the key
determinant for MV replication. Interestingly, analysis of patient tu-
mors from a clinical trial testing this OV, revealed that viral replication
in patient tumors was indeed inversely correlated with expression of
this resistance gene signature, supporting the translational value of
predictive profiles identified using preclinical model systems [45]. In
two Finnish studies, retrospective analysis of clinical variables and la-
boratory tests of over 200 patients treated with various adenovirus-
based OVs, revealed associations between treatment outcome and
several variables such as pretreatment neutralizing antibodies, tumor
burden, total leukocyte count, neutrophil counts, and HMGB1 baseline
status [46,47]. Together, these results highlight the importance of
collecting clinical data and samples. Future clinical studies are required
to validate these potential biomarkers of response and explore their
Fig. 1. “Near-patient” models that can be exploited to determine the direct and immuno-modulatory anti-tumor efficacy of candidate oncolytic viruses.
For the generation of patient-derived three-dimensional cultures (upper panel), the tissue is sliced and dissociated to obtain a single cell suspension. Subsequently,
the cell suspension is cultured in the presence of specific growth factors and/or extracellular matrices that facilitate the assembly of three-dimensional cellular
structures. Established three-dimensional cultures can be implemented for drug screening purposes.
Organotypic tumor tissue slices (lower panel) can be generated from neoplastic tissue types and from different locations in the human body (e.g. tissue of origin,
lymph nodes, metastases). The impact of treatment with a panel of oncolytic viruses can be examined and compared on cancer cells, stromal cells (including CAFs and
immune cells) and extracellular matrix molecules.
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relevance in also other types of OVs.
6. Choice of oncolytic virus candidates
With every individual researcher or research group typically
studying his/her ‘favorite’ virus, the question remains how we can
objectively determine which virus is optimal in a particular cancer or
even a specific patient. Here, we discuss some considerations in virus
selection, in addition to the obvious importance of tumor selectivity,
virus pathogenicity, immunogenicity, and stability. There are no gen-
eral rules for predicting how effective a virus can function as an on-
colytic agent. It goes without saying that the candidate virus should not
be pathogenic in humans, and not pose a risk to non-human hosts to
which a virus could be transmitted. Candidate viruses have been found
in all realms of virology, ranging from small non-enveloped and single-
stranded RNA viruses (e.g. attenuated poliovirus, a picornavirus) to
large enveloped double-stranded DNA viruses (e.g. attenuated herpes
simplex virus). The viruses can be of human origin (e.g. attenuated
human adenovirus type 5), or from animal origin (e.g. Newcastle dis-
ease virus, an avian paramyxovirus, or the rat H1 parvovirus [48]). For
some of the viruses there is a known safety profile, for instance because
the virus has been in use as a prophylactic vaccine. This is the case for
the Copenhagen strain of the vaccinia virus, a pox virus [49]. Further
modifications, such as deletion of the TK and the F1L gene, can increase
the tumor selectivity, and further reduce the chance of reversion to a
pathogenic phenotype. For other viruses such pre-existing safety profile
is absent, nevertheless, they could be developed for clinical evaluation
(e.g. Seneca Valley Virus, a picornavirus putatively of porcine origin
[50]).
Conclusively, an efficacious oncolytic virus should not cause any
disease, preferentially infect cancer cells over normal cells, efficiently
enters cancer cells, should not be hampered by pre-existing anti-viral
immune responses, and should kill all cancer cells in an immunogenic
manner that induces strong, systemic, and lasting anti-cancer im-
munity.
The cancer cells on the other hand show plasticity and diversity, and
this may allow cancer cell populations to escape from the viruses.
Therefore, it seems unrealistic that a single oncolytic virus used as a
monotherapy is able to cure cancers in all patients. As a result, they are
increasingly used in combination therapies. At this moment clinical
studies combining oncolytic viruses with immune checkpoint inhibition
are exploring whether the viruses can be used to activate the immune
system in those tumors exhibiting a paucity of tumor T cell infiltration,
the so called “cold” tumors [51]. For such an approach the availability
of an oncolytic virus that can infect the tumor cells and kill the cells in
an immunogenic manner, is a necessity.
7. The consortium approach
The promising (pre)clinical results obtained with oncolytic viro-
immunotherapy stimulates the further development of the approach,
especially for the aggressive cancer types for which the current therapy
options are grossly inadequate. The complexity and multi-faceted
nature of the approach make the translation of oncolytic virus research
into an effective therapeutic approach ambitious and challenging.
In 2012, the Dutch Oncolytic Viro-ImmunoTherapy (OVIT) con-
sortium was established. This multi-disciplinary consortium consists of
researchers and medical specialists of a dozen different departments in
three Dutch universities (Rotterdam, Leiden, and Utrecht), as well as
research centers such as Sanquin. The various participants include ex-
perts in oncology, virology, gene therapy, tumor biology, immunology,
as well as several excellent medical oncology specialists. They combine
their knowledge, expertise, research protocols, and preclinical models
with the goal to jointly develop and implement innovative viro-im-
munotherapeutic approaches for different types of cancer in the
Netherlands. Whereas traditionally, research groups only cover a
relatively narrow research area, this consortium approach accelerates
the execution of preclinical research and gears up for subsequent clin-
ical trials. The participants collectively address the challenges that are
faced in developing and implementing oncolytic viro-immunotherapy
in the clinic, such as the generation of oncolytic viruses with improved
potency and safety, the pre-clinical efficacy testing in near-patient
models, the development of strategies for overcoming heterogeneous
tumor responses, and the production of clinical-grade virus batches.
The primary focus lies on difficult-to-treat, aggressive cancer types that
urgently need new treatment strategies: pancreatic cancer, bladder
cancer, prostate cancer, and glioblastoma. To this end, participating
researchers of the OVIT consortium are currently performing com-
parative pre-clinical studies to define the therapeutic potential of ade-
novirus, Newcastle disease virus, and reovirus in near-patient models,
to identify which virus is most potent in which tumor, and to elucidate
underlying factors.
7.1. Viruses studied within the consortium
Adenoviruses are one of the most extensively studied oncolytic
viruses due to their good safety profile in clinical trials, relative
straightforward genetic modification, and feasibility to generate high-
titer virus batches. We have extensively evaluated the therapeutic po-
tential of the conditionally replicative adenovirus Ad5-Delta24RGD in
preclinical and clinical phase I/II studies for glioblastoma. This virus
has, in addition to the 24-bp deletion in E1A to improve cancer cell
selectivity, an expanded tropism toward αvβ3/αvβ5 integrins by in-
sertion of an Arg-Gly-Asp (RGD) motif into the fiber knob [52]. In our
preclinical studies, we have shown that Ad5-Delta24RGD lyses patient-
derived malignant glioma- and glioma stem cells, as well as both xe-
nograft and syngeneic glioblastoma tumors in mice [53–55]. This oc-
curs at a highly variable efficacy, with some being efficiently eradicated
whereas others are largely resistant to the virus. Analysis of T cell re-
activity and local cytokine levels revealed that the efficacy of this virus
seems to be dependent on the virus-induced anti-tumor immune re-
sponses [55]. Analysis of CSF samples of GBM patients treated with
Ad5-Delta24RGD, also revealed interpatient variability in cytokine in-
duction, and concurrent variability in macrophage activation toward
the proinflammatory phenotype [56]. Importantly, neutralizing anti-
bodies for Ad5 are prevalent in the human population. To circumvent
potential detrimental effects of pre-existing immunity on treatment
efficacy, current efforts aim to generate and test oncolytic adenoviruses
of non-human primate origin, in addition to Ad5-Delta24RGD.
Newcastle disease virus (NDV) has a natural avian host range but
also displays anti-tumor activity, with the degree of virulence in birds
correlating with the oncolytic potential [9]. Research efforts primarily
focus on the generation of NDVs with improved efficacy and safety
profile. We have performed preclinical tests with wild-type NDV, de-
monstrating anti-tumor activity in cancer models in vitro and in vivo, as
well as safety in non-human primates [57–59]. Moreover, we have
generated several modified NDVs harboring immunomodulatory
transgenes, which showed improved oncolytic efficacy, without dra-
matically affecting the virulence [58]. The virulence of NDV strains
poses an environmental risk, due to high susceptibility of poultry to
infection. Therefore, the safety profile of the virus required continuous
caution and care.
Reovirus has inherent oncolytic properties and is not associated
with serious human disease. Clinical trials have demonstrated safety
and moderate anti-tumor activity. Although presumably not the only
determinant [33], scarcity of reovirus receptors on tumors could confer
resistance to reovirus infection [60–62]. We previously described the
isolation of reoviruses with an expanded tropism, beyond the canonical
receptor JAM-A [63]. These mutants represent a promising virother-
apeutic agent to target those tumors that display limited expression or
inaccessibility of JAM-A.
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7.2. Clinical translation
Next to comparative studies to define the therapeutic potential of
the viruses, the production process of clinical-grade virus batches is
being streamlined within the OVIT research groups. Furthermore, the
consortium is involved in an extensive study on the risk assessment of
the oncolytic viruses, investigating the risks involved in virus stability,
shedding, and pathogenicity. This project is unique in that it convenes
twice a year with the stakeholders involved, including the local and
governmental authorities. In addition to the design of safe therapeutic
approaches, the acquired data will be used to establish a modernized
framework for regulations and reviewing of such approaches.
The consortium as well as its participating groups have benefitted
from the concerted visions and goals. The consortium teamed up with
the Dutch foundation “Overleven met Alvleesklierkanker” (Surviving
with Pancreatic Cancer), which provides support to participating
groups for distinct subprojects and invests in the infrastructure neces-
sary to produce clinical grade vectors. Moreover, the individual groups
members have successfully acquired grants for subprojects at several
other grant organizations. The involvement in the consortium has al-
lowed the participating groups to expand the ambition and will allow us
to become internationally competitive, while maintaining a large de-
gree of freedom to plan and perform clinical trials with one or more of
our oncolytic agents. This should lead to efficacious and affordable
treatment strategies in which oncolytic viruses are used to improve the
therapy for those cancer patients who currently have dismal prospects.
The help of the patients and the patient societies in this is key!
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